Gen-Wealth Partners’s Pacific Biosciences PACB Stock Holding History

Gen-Wealth Partners’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$92	Hold	70	–	–	﹤0.01%	720
2025 Q4	$131	Hold	70	–	–	﹤0.01%	683
2025 Q3	$90	Hold	70	–	–	﹤0.01%	678
2025 Q2	$87	Hold	70	–	–	﹤0.01%	639
2025 Q1	$83	Hold	70	–	–	﹤0.01%	614
2024 Q4	$128	Hold	70	–	–	﹤0.01%	640
2024 Q3	$151	Hold	70	–	–	﹤0.01%	653
2024 Q2	$96	Hold	70	–	–	﹤0.01%	641
2024 Q1	$263	Buy	+70	New	+$410	﹤0.01%	618

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Gen-Wealth Partners's PACB Position: Q1 2026 in Review

Gen-Wealth Partners held its Pacific Biosciences (PACB) position steady in Q1 2026 at 70 shares worth $92. The position accounts for ﹤0.01% of the portfolio, ranked #720.

Gen-Wealth Partners first reported a position in PACB in Q1 2024 and has held it in 9 quarters since. The position peaked at $263 in Q1 2024. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Gen-Wealth Partners held 70 shares of Pacific Biosciences worth $92 as of Q1 2026.
Gen-Wealth Partners left its Pacific Biosciences share count unchanged in Q1 2026.
Pacific Biosciences made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q1 2026, its #720 holding.
Gen-Wealth Partners first reported a position in Pacific Biosciences in Q1 2024 and has held it in 9 quarters since.
Gen-Wealth Partners's Pacific Biosciences position peaked at $263 in Q1 2024.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.